Slide 1: Osteopore Limited Investor Presentation – August 2020
Breakthrough 3D printed bioresorbable implants to assist with the natural stages of bone healing. Osteopore Limited (ASX: OSX) Investor Presentation – August 2020
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of th
Slide 3: Company Overview
Osteopore Limited (ASX: OSX) – Company Overview Osteopore Limited (ASX: OSX) is an Australian / Singapore-based medical technology company that specialises in the production of 3D printed bioresorbable implants to assist with the natural stages of bone healing. Osteopore’s products are fabricated in
Slide 4: Investment Highlights
Osteopore Limited (ASX: OSX) 4 Investment Highlights Revenue Generating Regulatory Clearance Scalable Business Model Over A$1.3m in revenues for the twelve Osteopore’s products have secured key Proven wholesale / distributor business month period to 30 June 2020, with strong regulatory hurdles inclu
Slide 5: Quarterly Revenue Growth
Osteopore Limited (ASX: OSX) Quarterly Revenue Growth Encouraging sales growth despite difficult global macroeconomic environment caused by COVID-19 $348,000 $341,000 Revenue (S$) $270,000 $350,000 $279,000 $300,000 $228,000 $250,000 $167,000 $200,000 $150,000 $100,000 $50,000 $- CY2019 Q1 CY2019 Q2
Slide 6: Strategic Milestones Since IPO
Osteopore Limited (ASX: OSX) Strategic Milestones Since IPO Osteopore has achieved significant strategic milestones over the past 11 months since IPO Secured initial US Gained Australian Established Success in Building team and Distribution TGA approval for partnership for orthopaedic manufacturing
Slide 7: FY2021 Strategic Commercial Priorities
Osteopore Limited (ASX: OSX) 7 FY2021 Strategic Commercial Priorities 1 2 3 US Market Penetration New Markets Revenue Growth Build market penetration through existing Establish new geographic markets in Australia, Increase underlying revenue from current distributor and develop new distribution Euro
Slide 8: Recent U.S. Distribution Agreement
Osteopore Limited (ASX: OSX) 8 Recent U.S. Distribution Agreement Bioplate is an established market leader in neurosurgery around the world, with two decades of experience and strong relationships with doctors, hospitals and health services Bioplate will cover all technical support requirements for
Slide 9: Opportunities in Multi-Billion Dollar Global Markets
Osteopore Limited (ASX: OSX) Opportunities in Multi-Billion Dollar Global Markets Current Sales Current market opportunities Current sales of Osteopore products are pre-dominantly (Bone Graft substitutes, US$3.9bn by 2025)1 in Cranial / Maxillofacial (CMF) area, which represents Permanent Implants s
Slide 10: Technology Overview
Technology verview
Slide 11: Current Approaches to Bone Regeneration
Osteopore Limited (ASX: OSX) Current Approaches to Bone Regeneration Currently, there are three main treatment Bone Graft Permanent Implants Bio-Materials strategies to augment the bone-regeneration process, including the 'gold standard' bone A surgical procedure where bone Permanent materials used
Slide 12: Customisable 3D printed bioresorbable implants to enable natural bone healing
Customisable 3D printed bioresorbable implants to enable the natural stages of bone healing across multiple applications. Highly customisable Naturally dissolves Leaves only healthy Reduces post surgery Unlikely inflammation to biomimic different over time bone tissue complication rates or infection
Slide 13: Proprietary Bioresorbable Scaffold Technology
Osteopore Limited (ASX: OSX) Proprietary Bioresorbable Scaffold Technology Osteopore’s proprietary 3D printed polymer scaffold is made up of Osteopore Scaffold biomimetic microstructures that facilitate natural tissue regeneration after insertion into the human body. Angiogenesis – Early stage regen
Slide 14: Landmark 10-Year Clinical Study
Osteopore Limited (ASX: OSX) Landmark 10-Year Clinical Study A 10-year clinical study by the National University Hospital in Singapore, illustrated that Osteoplug implants are capable of restoring the human skeleton with a reduced risk of post-surgery complications, commonly associated with permanen
Slide 15: Products & Applications
Osteopore Limited (ASX: OSX) 15 Products & Applications Bioresorbable implant that is Bioresorbable implant that is used in Provides a durable, biodegradable Patient Specific Implants (PSI) based on used for covering Burr Holes craniofacial surgery to repair various method of filling the void follow
Slide 16: Clinical Success - Patient Specific Implants
Osteopore Limited (ASX: OSX) Clinical Success - Patient Specific Implants Bone Defect Early Mineralisation Walking Bone Remodeling 150mm bone loss due to Initial osseous ingrowth with Able to walk without Complete bone bridging tumor resection 20kg partial weight-bearing assistance from proximal to
Slide 17: Osteopore Offers Unique Therapeutic Value Proposition
Osteopore Limited (ASX: OSX) 17 Osteopore Offers Unique Therapeutic Value Proposition There are no other FDA or CE Mark cleared products that offer Microporous Osteopore’s key technology characteristics – bio-resorption and (Biomimetic Structure) biomimetic structure - which offer improved patient o
Slide 18: Market Opportunities & Growth Strategy
Market Opp rtunities & Growth Strategy
Slide 19: Business and Revenue Model
Osteopore Limited (ASX: OSX) Business and Revenue Model Distribution Networks Given the high wholesale margins and low capital intensity of the 3-D printing-based manufacturing process, Osteopore is focused on building distribution networks for its products while retaining control over the key manuf
Slide 20: Revenue Growth Strategy
Osteopore Limited (ASX: OSX) 20 Revenue Growth Strategy Osteopore is now looking to build value through short, medium and long term strategic goals. Revenue Expansion o Growth in revenue from existing Asian markets Phase One Increase underlying revenue from its o Establish new geographic markets (US
Slide 21: Phase One Revenue Expansion
21 Osteopore Limited (ASX: OSX) Phase ne Revenue Expansion The Company aims to enhance market penetration of the Phase Two commercially ready Osteoplug, Osteomesh and Osteostrip products Phase Three Building underlying revenue base organically from Asian markets and building distribution networks in
Slide 22: Phase Two New Therapeutic Segments
22 Osteopore Limited (ASX: OSX) Phase One Cranial and Facial Phase Tw Dental Orthopaedic Phase Three Osteopore has developed an enhanced bioresorbable 3D-printed dental plug which Osteopore has successfully conducted first in promotes bone growth in the jaw, reducing human trials using the Osteopore
Slide 23: Phase Three Future Horizons
23 Osteopore Limited (ASX: OSX) Phase One Phase Two Phase Three Future Horizons Accelerating Bone Regeneration Osteopore is investigating the viability of incorporating bioactive materials into polycaprolactone polymer material, which could be used to improve patient outcomes. These new polymer comp
Slide 24: Building Blocks in Place for Executing Growth Strategy
Building bl cks in place for executing growth strategy
Slide 25: Scalable & Customisable Manufacturing
Integration of Medical Imaging, Computational Osteopore Limited (ASX: OSX) Mechanics & Biomaterials Technology Scalable & Customisable Step One The hospital undertakes a CT scan. Manufacturing. 3D printing process to customise products Step Two Osteopore uses third party software to digitise the and
Slide 26: Global Regulatory Approval
Osteopore Limited (ASX: OSX) Global Regulatory Approval Current regulatory clearances Potential Future clearances 26
Slide 27: Intellectual Property
Osteopore Limited (ASX: OSX) Intellectual Property Osteopore technology is supported by granted patents from leading Singaporean research institutions. Method for Bioresorbable 3-D Bioresorbable Resorbable Bioresorbable- Fabricating a Plug Implants Scaffolds for Tissue Scaffolds for Bone Magnesium F
Slide 28: Corporate and Capital Structure
Osteopore Limited (ASX: OSX) Corporate and Shares on Issue1 117.2m Capital Structure Capital Structure Total Options on Issue2 13.1m o No debt Market Cap @ $0.53c3 $62.1m o 42.6m shares under escrow for 12-24 months EV @ $0.533 $51.8m o Options could provide an additional $2.8m in capital Pro Forma
Slide 29: Placement & Use of Funds
Osteopore Limited (ASX: OSX) Placement & Use of Funds Osteopore has recently completed a capital raising to raise $8.5 million to fund ongoing growth initiatives Indicative Use of Funds $m Business development $3.0 Clinical trials (orthopaedic, dental) $2.0 Product development and R&D $1.0 Working c
Slide 30: Founder, Management and Board of Directors
Osteopre Limited (ASX: OSX) Partner of Ventnor Capital, Brett Sandercock Non-Executive Chairman or Director of a number of Founder, Management Non-Exec Chairman ASX listed entities and Board of Directors Current CFO of Resmed (ASX:RMD / NYSE: RMD) Stuart Carmichael Non-Exec Director Prof Teoh Swee H
Slide 31: Key Risks
Osteopore Limited (ASX: OSX) 31 Key risks Company specific risks Risk Summary Osteopore is currently securing market entry and market penetration across a number of global territories. The Company cannot guarantee the rate of market Revenue Risk penetration or revenue growth or the timing of market
Slide 32: Key Risks
32 Osteopore Limited (ASX: OSX) Key risks Company specific risks Risk Summary Intellectual property Osteopore currently relies on intellectual property laws to protect its IP. There is a risk that its intellectual property may be infringed and a risk that Osteopore risk may not be able to successful
Slide 33: Key Risks
33 Osteopore Limited (ASX: OSX) Key risks Company specific risks Risk Summary Osteopore licences software from a third-party provider for use in development of fused deposition modelling 3D printing instruction software. Whilst there are Licenses risk other alternative software providers, there is a
Slide 34: Key Risks
34 Osteopore Limited (ASX: OSX) Key risks General risks Risk Summary There are inherent risks associated with investment in any listed company. The new shares under the Placement do not guarantee payment of dividends, return Nature of on capital or maintenance of capital or value. No assurances can
Slide 35: International Offer Restrictions
35 International Offer Restrictions This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold in t
Slide 36: Investor Presentation 2020
Investor Presentation 2020 Goh Khoon Seng Geoff Pocock Chief Executive Officer Executive Director M +65 9670 0812 M +61 412 194 373 E: goh_khoon_seng@osteopore.com E: geoff_pocock@osteopore.com